Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

12.59 +0.76 (+6.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,440,321
Open 11.82
Bid (Size) 12.04 (10)
Ask (Size) 13.16 (4)
Prev. Close 11.83
Today's Range 11.79 - 12.68
52wk Range 9.590 - 73.03
Shares Outstanding 68,641,116
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BMO Initiates Coverage On This Gene Editing Spearhead
 
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-54.43%
-54.43%
1 Month
+9.10%
+9.10%
3 Month
-41.03%
-41.03%
6 Month
-54.43%
-54.43%
1 Year
-77.07%
-77.07%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine: Q1 Earnings Insights
Via Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
Via InvestorPlace
Editas Medicine's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Via Benzinga
Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
Via Benzinga
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
27 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Via Investor's Business Daily
Expert Ratings For Editas Medicine
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Editas Suddenly Terminates Chief Medical Officer Without An Explanation
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.